Linda Zuckerman
Chief Executive Officer at Xcede Technologies, Inc.
Profile
Linda Zuckerman is the President & Chief Executive Officer at Xcede Technologies, Inc. She previously worked as a Director-Preclinical Development at ZymoGenetics, Inc. and as a Principal at Genentech, Inc. From 2008 to 2011, she was the Vice President-PreClinical Development at ProFibrix BV.
Dr. Zuckerman earned a doctorate degree from The University of Chicago in 1996.
Linda Zuckerman active positions
| Companies | Position | Start |
|---|---|---|
Xcede Technologies, Inc.
 Xcede Technologies, Inc. Medical SpecialtiesHealth Technology Part of Dynasil Corp. of America, Xcede Technologies, Inc. develops innovative hemostatic and sealant products for surgical applications. The company is based in Rochester, MN. Linda Zuckerman has been the CEO of the company since 2015. | Chief Executive Officer | 2015-08-31 |
Former positions of Linda Zuckerman
| Companies | Position | End |
|---|---|---|
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Corporate Officer/Principal | 2011-11-30 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Training of Linda Zuckerman
| The University of Chicago | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Xcede Technologies, Inc.
Xcede Technologies, Inc. Medical SpecialtiesHealth Technology Part of Dynasil Corp. of America, Xcede Technologies, Inc. develops innovative hemostatic and sealant products for surgical applications. The company is based in Rochester, MN. Linda Zuckerman has been the CEO of the company since 2015. | Health Technology |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Linda Zuckerman
